In recent years, the worldwide spread of the so-called high-risk clones of multidrug-resistant
or extensively drug-resistant (MDR/XDR) Pseudomonas aeruginosa has become a public …

Background: Infections caused by multi-drug-resistant Gram-negative bacteria, particularly
Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae, that …

Background The β-lactamase inhibitor relebactam can restore imipenem activity against
imipenem-nonsusceptible gram-negative pathogens. We evaluated imipenem/relebactam …

The emergence of multidrug-resistant Gram-negative bacteria that cause nosocomial
infections is a growing problem worldwide. Colistin was first introduced in 1952 and was …

In the face of diminishing therapeutic options for the treatment of infections caused by
multidrug-resistant, Gram-negative bacteria, clinicians are increasingly using colistin and …

The emergence of carbapenem resistance in Enterobacteriaceae is an important threat to
global health. Reported outcomes of infections with carbapenem-resistant …

Background. Extensively drug-resistant (XDR) Acinetobacter baumannii may cause serious
infections in critically ill patients. Colistin often remains the only therapeutic option. Addition …

Resistance to antibiotics has increased dramatically over the past few years and has now
reached a level that places future patients in real danger. Microorganisms such as …

Colistin and polymyxin B have indistinguishable microbiological activity in vitro, but they
differ in the form administered parenterally to patients. Polymyxin B is administered directly …

Objectives This study investigated the exposure–response relationships between unbound
colistin in plasma and antibacterial activity in mouse thigh and lung infections. Methods …